Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rui Li, Xiaofei Zhou, Hongjuan Yao & Liang Li. (2020) Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. Journal of Drug Targeting 28:9, pages 861-872.
Read now
Read now
Sarah Lehmann, René Allard & Yvonne-Beatrice Boehler. (2019) The European Medicines Agency Clinical Data Website Enables Insights Into Clinical Development Timelines And Strategy. Open Access Journal of Clinical Trials 11, pages 37-56.
Read now
Read now
Mariacarmela Santarpia, Alessia Liguori, Niki Karachaliou, Maria Gonzalez-Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla & Rafael Rosell. (2017) Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy 8, pages 109-125.
Read now
Read now
Brian Ko, Daniel Paucar & Balazs Halmos. (2017) EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer: Targets and Therapy 8, pages 147-159.
Read now
Read now
Antonio Rossi, Lucia Anna Muscarella, Concetta Di Micco, Cristiano Carbonelli, Vito D’alessandro, Stefano Notarangelo, Giuseppe Palomba, Gerardo Sanpaolo, Marco Taurchini, Paolo Graziano & Evaristo Maiello. (2017) Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Metabolism & Toxicology 13:12, pages 1281-1288.
Read now
Read now
Articles from other publishers (27)
K. G. Kulikov, T. V. Koshlan & A. P. Golovitsky. (2023)
A Paradigm Shift in Experimental Biochemistry:
A Priori
Estimation of Physical Parameters of Biomolecules
. Biophysical Reviews and Letters 18:01, pages 23-106.
Crossref
Crossref
Houssein Chhouri, David Alexandre & Luca Grumolato. (2023) Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. Cancers 15:2, pages 504.
Crossref
Crossref
Hanan A. Bin Saeed, Maha H. Daghestani, Khushboo Ambreen, Mazin H. Daghestani, Sabah A. Al-Zahrani, Hussah Alobaid & Nawal M. AL-Malahi. (2022) Low Dose of Green Synthesized Silver Nanoparticles is Sufficient to Cause Strong Cytotoxicity via its Cytotoxic Efficiency and Modulatory Effects on the Expression of PIK3CA and KRAS Oncogenes, in Lung and Cervical Cancer Cells. Journal of Cluster Science.
Crossref
Crossref
Ajay P. Jayan, K. R. Anandu, Krishnadas Madhu & V. N. Saiprabha. (2022) A pharmacological exploration of targeted drug therapy in non-small cell lung cancer. Medical Oncology 39:10.
Crossref
Crossref
Ze‐Yu Fang, Yi‐Heng Zhang, Chong‐Hao Chen, Qi Zheng, Peng‐Cheng Lv, Lei‐Qiang Ni, Juan Sun & Yuan‐Feng Wu. (2022) Design, Synthesis and Molecular Docking of Novel Quinazolinone Hydrazide Derivatives as EGFR Inhibitors. Chemistry & Biodiversity 19:6.
Crossref
Crossref
T. V. Koshlan & K. G. Kulikov. (2022) Analysis to determine the effect of mutations on binding to small chemical molecules. Journal of Bioinformatics and Computational Biology 20:02.
Crossref
Crossref
Andreas Stein, Persefoni Hilken née Thomopoulou, Corazon Frias, Sina M. Hopff, Paloma Varela, Nicola Wilke, Arul Mariappan, Jörg-Martin Neudörfl, Alexey Yu Fedorov, Jay Gopalakrishnan, Benoît Gigant, Aram Prokop & Hans-Günther Schmalz. (2022) B-nor-methylene Colchicinoid PT-100 Selectively Induces Apoptosis in Multidrug-Resistant Human Cancer Cells via an Intrinsic Pathway in a Caspase-Independent Manner. ACS Omega 7:3, pages 2591-2603.
Crossref
Crossref
Akhileshwar Kumar Srivastava, Dhruv Kumar, Divya Singh & Rajesh Kumar Singh. 2022. Xenobiotics in Chemical Carcinogenesis. Xenobiotics in Chemical Carcinogenesis
245
259
.
Jacqueline Ramirez, Larry K. House & Mark J. Ratain. (2021)
Influence of
N
‐acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib
. British Journal of Clinical Pharmacology 87:11, pages 4313-4322.
Crossref
Crossref
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters & Omidreza Firuzi. (2021) Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Critical Reviews in Oncology/Hematology 160, pages 103234.
Crossref
Crossref
Phoebe F. Lamie, Asmaa M. El-Kalaawy, Noha S. Abdel Latif, Laila A. Rashed & John N. Philoppes. (2021) Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure–activity relationship and biological activity as potential antitumor and anticonvulsant agents. European Journal of Medicinal Chemistry 214, pages 113222.
Crossref
Crossref
Tadashi Honda & Iwao Ojima. 2021. The Curious World of Fluorinated Molecules. The Curious World of Fluorinated Molecules
241
276
.
Peter C. Pan & Rajiv S. Magge. (2020) Mechanisms of EGFR Resistance in Glioblastoma. International Journal of Molecular Sciences 21:22, pages 8471.
Crossref
Crossref
Cheng-Ta Chung, Kai-Chia Yeh, Chia-Huei Lee, Yun-Yu Chen, Pai-Jiun Ho, Kai-Yen Chang, Chieh-Hsin Chen, Yiu-Kay Lai & Chiung-Tong Chen. (2020) Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice. Pharmacological Research 161, pages 105183.
Crossref
Crossref
Yuan Liang, Tiehua Zhang & Jie Zhang. (2020) Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy. Pharmacological Research 161, pages 105164.
Crossref
Crossref
Surya K. Tripathi, Kamal Pandey, Kannan R. R. Rengasamy & Bijesh K. Biswal. (2020) Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. Medicinal Research Reviews 40:6, pages 2132-2176.
Crossref
Crossref
Ayah Abdeldayem, Yasir S. Raouf, Stefan N. Constantinescu, Richard Moriggl & Patrick T. Gunning. (2020) Advances in covalent kinase inhibitors. Chemical Society Reviews 49:9, pages 2617-2687.
Crossref
Crossref
Matthias Gehringer. 2021. Proteinkinase Inhibitors. Proteinkinase Inhibitors
43
94
.
Nele Van Der Steen, Karen Zwaenepoel, Giulia Mazzaschi, Rosa A. Luirink, Daan P. Geerke, Ken Op de Beeck, Christophe Hermans, Marcello Tiseo, Paul Van Schil, Filip Lardon, Paul Germonpré, Christian Rolfo, Elisa Giovannetti, Godefridus J. Peters & Patrick Pauwels. (2019) The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies. Molecules 24:24, pages 4443.
Crossref
Crossref
Rashmi R. Shah & Devron R. Shah. (2019) Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology. Drug Safety 42:2, pages 181-198.
Crossref
Crossref
Harun M. Patel, Rahul Pawara & Sanjay J. Surana. 2019. Third Generation EGFR Inhibitors. Third Generation EGFR Inhibitors
25
43
.
Daniel de Klerk, Richard Honeywell, Gerrit Jansen & Godefridus Peters. (2018) Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers 10:12, pages 503.
Crossref
Crossref
Zachary Schrank, Gagan Chhabra, Leo Lin, Tsatsral Iderzorig, Chike Osude, Nabiha Khan, Adijan Kuckovic, Sanjana Singh, Rachel Miller & Neelu Puri. (2018) Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Cancers 10:7, pages 224.
Crossref
Crossref
Keita Masuzawa, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima & Tomoko Betsuyaku. (2017) Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. Oncotarget 8:62, pages 105479-105491.
Crossref
Crossref
Harun Patel, Rahul Pawara, Azim Ansari & Sanjay Surana. (2017) Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. European Journal of Medicinal Chemistry 142, pages 32-47.
Crossref
Crossref
Julian Engel, Steven Smith, Jonas Lategahn, Hannah L. Tumbrink, Lisa Goebel, Christian Becker, Elisabeth Hennes, Marina Keul, Anke Unger, Heiko Müller, Matthias Baumann, Carsten Schultz-Fademrecht, Georgia Günther, Jan G. Hengstler & Daniel Rauh. (2017) Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry 60:18, pages 7725-7744.
Crossref
Crossref
Martin Svatoň, Kristýna Hrdá & Miloš Pešek. (2017) Osimertinib - a new treatment option for patients with EGFR mutation T790M. Onkologie 11:2, pages 72-77.
Crossref
Crossref